Janux Therapeutics, Inc. (JANX) Cash Flow Statement

The near-zero operating cash flow against a $22M net loss suggests that the reported loss is not fully translating into cash burn, largely due to a substantial working capital inflow. This may indicate timing of collaboration payments or deferred revenue recognition, but investors should monitor whether this is a one-time effect or a recurring pattern. The OCF/NI ratio of -0.01 in 2026Q2 contrasts sharply with the 0.89 in 2025Q4, highlighting quarter-to-quarter volatility in cash conversion.

Excluding the anomalous 2026Q2, FCF has been consistently negative, ranging from -$12.6M to -$28.6M, reflecting the company's heavy investment in R&D ahead of commercialization. The FCF margin, though negative, is not meaningful given the negligible revenue base; the absolute burn rate is the critical metric. With cash and equivalents near $52M, the current burn implies a runway of roughly three to four quarters, assuming no additional capital raises or milestone inflows.

The negligible capex relative to revenue and the high R&D spend suggest that JANX's cash burn is driven by clinical trial costs and personnel, not physical assets. This implies that the company's scalability is tied to its ability to manage trial execution and partnerships rather than capital-intensive manufacturing. The low capital intensity may also mean that future cash needs will be primarily for clinical development, not infrastructure.

The large positive working capital adjustment in 2026Q2, which offset the net loss, appears to be driven by a significant inflow from collaboration partners or a reduction in receivables. This volatility suggests that operating cash flow is not a reliable indicator of underlying business performance, as it is heavily influenced by the timing of milestone payments and expense accruals. Investors should focus on the net burn rate, which adjusts for these swings, to assess the company's true cash consumption.

The absence of capital returns is consistent with a company in the clinical stage, where preserving cash for development is paramount. The $18.3M stock-based compensation in 2026Q2, while non-cash, represents a significant dilution cost that investors should weigh against the company's cash burn. The reliance on equity funding, as indicated by the low debt-to-equity ratio, suggests that future capital raises may be necessary, potentially diluting existing shareholders.

The significant divergence between net income and operating cash flow indicates that a substantial portion of reported losses are non-cash, primarily stock-based compensation and depreciation. This suggests that the actual cash burn is lower than the accounting loss, but still substantial. The cumulative gap also reflects the impact of working capital changes, which have been volatile. Investors should adjust for these non-cash items to gauge the true cash runway and the potential need for future financing.